Nr | Age at diagnosis (yrs) | Gender | FAB | Cytogenetic Features | Molecular Biology | WBC at diagnosis (.10 9 /L) | WBC before GO (.10 9 /L) | Nb of Relapses | Treatment before relapse or GO |
---|---|---|---|---|---|---|---|---|---|
#1 | 1.8 | M | JMML | N | N | 25.2 | 1.2 | R | Other |
#2 | 1.1 | M | AML7 | N | N | 23.0 | 5.0 | 1 | CT♣ |
#3 | 1.1 | F | AML7 | 53,XX,+X,t(1;22)(p13;q13)+5,+6,+19,+20,+21 [18] | OTT/MAL | 9.0 | 8.2 | 2 | CT♣ IL2 CB-SCT |
#4 | 14.0 | F | AML1 | 47,XX,+8 [20] | N | 27.7 | 2.2 | 1 | CT♣ |
#5 | 14.7 | M | MDS/AML6 | N | N | 1.5 | 0.9 | R | CT♣ MUD-SCT |
#6 | 17.2 | F | AML2 | 46,XX,t(6;9)(p23;q34) [25] | DEK/CAN | 3.3 | 10.9 | 1 | CT♣ |
#7 | 2.8 | M | MDS/AML7 | 46,XY,del(3)(q24;q26) [6] | N | 11.4 | 22.0 | R | CT♣ |
#8 | 2.5 | M | AML7 | N | N | 4.8 | 7.4 | 1 | CT♣ |
#9 | 1.0 | F | AML7 | 46,t(2;16) [20] | N | 20.0 | 4.0 | 1 | CT♣ |
#10 | 8.2 | M | AML5 | 46,XY,t(6;11)(q26;q23),del(12)(p11;p12) [17] | N | 38.0 | 0.2 | 1 | CT♣ |
#11 | 13.5 | M | AML6 | 47,XY,del(3)(q23;qter), +8 [9] | N | 2.6 | 1.2 | 1 | Other |
#12 | 10.0 | F | AML2 | 45,XX,-7 [23] | N | 26.0 | 2.4 | 1 | CT♣ |